Related references
Note: Only part of the references are listed.18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence
Fahad Marafi et al.
CLINICAL NUCLEAR MEDICINE (2020)
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
Naoya Nagaya et al.
PLOS ONE (2020)
High uptake of 68Ga-PSMA and 18F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes
Dennis Oliveira et al.
EJNMMI RESEARCH (2020)
Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Francesco Bertagna et al.
CURRENT RADIOPHARMACEUTICALS (2020)
F-18-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
Rudolf A. Werner et al.
THERANOSTICS (2020)
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Ulrich Herrlinger et al.
LANCET (2019)
68Ga-PSMA-11 PET enables accurate detection of recurrent disease
Conor A. Bradley
Nature Reviews Clinical Oncology (2019)
Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients
Norbert Galldiks et al.
NEURO-ONCOLOGY (2019)
Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma
Dian Jiao et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2019)
What is the best PET target for early biochemical recurrence of prostate cancer?
Jeremie Calais et al.
LANCET ONCOLOGY (2019)
Management of Glioblastoma, Present and Future
Nancy Ann Oberheim Bush et al.
WORLD NEUROSURGERY (2019)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf et al.
NATURE (2019)
Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme
Parvin Mahzouni et al.
ADVANCED BIOMEDICAL RESEARCH (2019)
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Antje Wick et al.
NEURO-ONCOLOGY (2018)
Identification of time-to-peak on dynamic F-18-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma
Bogdana Suchorska et al.
NEURO-ONCOLOGY (2018)
Utility of 68Ga-PSMA-11 PET/CT in Imaging of GliomaA Pilot Study
Arun Sasikumar et al.
CLINICAL NUCLEAR MEDICINE (2018)
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives
Philipp Backhaus et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody
Masahide Matsuda et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas
Roberto A. Salas Fragomeni et al.
CLINICAL NUCLEAR MEDICINE (2018)
Primary brain tumours in adults
Sarah Lapointe et al.
LANCET (2018)
177Lu-PSMA Radioligand Therapy for Prostate Cancer
Wolfgang P. Fendler et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller et al.
LANCET ONCOLOGY (2017)
The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
Marcus Unterrainer et al.
NEURO-ONCOLOGY (2017)
Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer
Lars Henning Schmidt et al.
PLOS ONE (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
Diagnostic Value of Ga-68 PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis
Arun Sasikumar et al.
CLINICAL NUCLEAR MEDICINE (2017)
Prostate-Specific Membrane Antigen-Targeted Imaging With [18F] DCFPyL in High-Grade Gliomas
Roberto Andres Salas Fragomeni et al.
CLINICAL NUCLEAR MEDICINE (2017)
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma
Michael J. P. Crowley et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller et al.
CLINICAL CANCER RESEARCH (2015)
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM
Bogdana Suchorska et al.
NEUROLOGY (2015)
Expression of Prostate-Specific Membrane Antigen in Lung Cancer Cells and Tumor Neovasculature Endothelial Cells and Its Clinical Significance
Hai-long Wang et al.
PLOS ONE (2015)
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases
Natsuko Nomura et al.
CANCER CELL INTERNATIONAL (2014)
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing
Betty Y. S. Kim et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Multiforme
A. Gabriella Wernicke et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2011)
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique
P. Mhawech-Fauceglia et al.
HISTOPATHOLOGY (2007)
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer
JR Mesters et al.
EMBO JOURNAL (2006)
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
MI Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
N Schülke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
